Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2016

View Archived Issues

Kymab and MD Anderson form immuno-oncology R&D alliance

Jubilant Biosys and Sanofi Deutschland collaborate in metabolic disorders

Memorial Sloan Kettering and Juno Therapeutics sign licensing agreement for MUC-16 binder

Dual Therapeutics and Bristol-Myers Squibb establish collaboration in cancer

Illumina launches cancer diagnostic company GRAIL

Pfizer announces investments and a research collaboration

Diffusion Pharmaceuticals completes merger with RestorGenex

FDA grants fast track designation for GC-4419

Adenoviral GDEPT combined with radiotherapy safe and effective in phase II prostate cancer study

Tobira Therapeutics initiates a program to evaluate cenicriviroc for the treatment of PSC

FDA grants orphan drug designation for WT1 cancer vaccine for the treatment of AML

Innate Pharma signs new licensing agreements with Orega, Sanofi

Mylan to codevelop six Momenta biosimilars

Medshine Discovery patents PI3Kalpha inhibitors

Cisen Pharmaceutical and Medshine Discovery report mTOR/PI3Kalpha inhibitors

Researchers attempt to find tools for early diagnosis of pancreatic cancer

Shire and Baxalta to combine

High-dose monovalent inactivated poliovirus type 2 vaccine is safe and immunogenic in infants

Theravance changes name to Innoviva

Exelixis files MAA for cabozantinib in RCC

Topical quinolone antibacterial Zebiax launched in Japan

Protagonist Therapeutics begins phase I study of PTG-100

Zogenix initiates first phase III trial of ZX-008 for Dravet syndrome

Merck KGaA agrees terms to return evofosfamide rights to Threshold Pharmaceuticals

Archexin in combination with everolimus shows promise for RCC

MabTech completes Chinese phase III trials for biosimilars STI-001 and STI-002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....